On October 28, 2025, Genprex, Inc. agreed to sell 377,780 shares of its common stock at $9.00 per share in a registered direct offering, with expected proceeds of approximately $3.0 million for working capital. Additionally, the agreement includes warrants for up to 755,560 shares and the possibility of raising an additional $6.6 million if these warrants are fully exercised.